Published in Diabetes Week, May 19th, 2008
"There is recent interest in SGLT2 as a target for the treatment of type II diabetes using selective inhibitors based on the structure of the phenylglucoside, phlorizin (phloretin-2 '-beta-glucoside). In this study, we examined the inhibition of alpha-methyl-D-glucopyranose transport by phlorizin and a new candidate drug, sergliflozin-A [(2-[4-methoxyphenyl]methyl)phenyl...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.